Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol -

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Information type: Randomised controlled trials
Source: European Heart Journal
Specialities: Cancers | Cardiovascular system disorders
Summary
This 2x2 factorial RCT (n=130) found that candesartan, but not metoprolol reduced LVEF decline vs placebo in patients on anathracyclines for early breast cancer. LVEF decline = 2.6 with placebo vs 0.8 for candesartan (p=0.026).
UKMi comment
A related editorial discusses the results of this trial. It notes that cancer drug-associated HF is a substantial health problem and that the study only found small effects with an ARB on LVEF. It suggests that a better understanding of the pathophysiology may lead to the design of specific, targeted drug therapies. In addition, larger trials are needed with longer follow-up to identify beneficial treatment strategies for these patients.
Related links: Editorial